clinical trial · NCT05083182
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
Janssen Research & Development, LLC·phase3·active not recruiting·n = 50
Arthritis, JuvenileUstekinumabGuselkumab
brief summary
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
started
Aug 30, 2022
primary completion
Jan 12, 2026
completion
Dec 5, 2026
last updated
Apr 13, 2026
official title
A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol